ALIV's ACT Programme Since 2015: What a Decade of Experience Has Taught Us | ALIV

ALIV began offering Autologous Cell Therapy in India in 2015 — at a time when regenerative medicine in the Indian private healthcare market was almost entirely theoretical marketing, with very few clinics capable of actually conducting rigorous autologous cell-based procedures. A decade later, the landscape has changed considerably — but the commitment to autologous sourcing, honest outcome framing, and clinical rigour that defined ALIV's programme in 2015 remains its most important differentiator. This article reflects on what a decade of ACT clinical experience has genuinely taught us about the therapy, its applications, and its patients.

What the Clinical Experience Has Confirmed

Appropriate patient selection is the strongest predictor of meaningful response. The patients ALIV sees today who respond best are those selected using the criteria the clinical team has refined over ten years: moderate rather than advanced disease stage; adequate residual tissue regenerative capacity; realistic expectations aligned with the evidence; and commitment to the complementary interventions (physiotherapy, nutritional optimisation, lifestyle modification) that support ACT's biological effect. Patients who were accepted early in the programme without these selection criteria consistently produced less impressive outcomes — and those outcomes informed the more rigorous selection standards applied today.

The combination of IV therapy and ACT consistently outperforms ACT alone. This finding — which is mechanistically plausible but needed clinical confirmation — has become one of the most consistent observations across ALIV's patient cohort. The pre-ACT nutritional optimisation and post-ACT metabolic support provided by IV micronutrient therapy create the biochemical environment in which ACT's paracrine signals produce the best tissue response. See: ACT and IV therapy combined.

Neurological applications require the most patience. Ten years of neurological ACT has made the clinical team very careful about timeline expectations in Parkinson's, Alzheimer's, and SCI — and very respectful of the emotional complexity of these conversations with patients and families. The patients who benefit most are those whose families understand that the goal is improved quality of life, not cure, and who commit to the rehabilitation work alongside ACT.

Reproductive applications have the most variable and most emotional outcome stories. Dr. Tandulwadkar's fertility ACT programme has produced some of ALIV's most extraordinary outcomes — and some of its most difficult conversations. The biology of fertility is complex, individual, and rarely fully predictable. Honest pre-procedure counselling about the experimental nature of reproductive ACT is, in Dr. Tandulwadkar's clinical opinion, the most important component of ethical reproductive medicine practice.

Where the Field Is Going

Regenerative cell therapy in India is evolving rapidly. ALIV's clinical team monitors the global literature on MSC therapy, autologous growth factor applications, and emerging combination approaches. Several directions that ALIV sees as particularly promising: the combination of ACT with senolytic interventions (targeting senescent cells to improve the regenerative environment before ACT delivery); the integration of biomarker-guided patient selection to improve response prediction; and the expanding evidence base for ACT in metabolic disease — particularly NASH/MASH, where the unmet need and mechanistic rationale are both very strong. ALIV's ten-year position in this field means the clinical team brings practical, patient-level experience to these emerging developments — not just academic literature review. See: the complete ACT patient guide.

How does ALIV ensure the quality of its ACT preparations?

Quality assurance at ALIV involves: same-day fresh preparation (no banked or frozen material); on-site laboratory processing with trained staff; documentation of cell counts and viability at each processing stage; sterility checks on the final preparation before administration; and a patient-specific preparation record maintained for clinical audit purposes. ALIV does not use third-party laboratories or outsource cell processing — the clinical team controls the quality chain from harvest to administration.

Can patients access ALIV's clinical outcome data?

ALIV maintains an internal clinical outcomes database tracking patient response across conditions. Summary outcomes data is available to patients considering ACT as part of the pre-consultation information pack — providing the most accurate honest picture of response rates and outcome distributions in ALIV's own clinical cohort. This is the evidence base most relevant to prospective patients: not abstract trial data from different populations and protocols, but ALIV's own clinical experience with its specific patient population and procedures.